People's republic of china *These authors contributed equally to this work Objective: The aim of this study was to address the association between the Ile462Val polymorphism in the gene encoding cytochrome P450 1A1 (CYP1A1) and the risk of head and neck cancer (HNC).
Introduction
Head and neck cancer (HNC) is a broad term that encompasses epithelial malignancies that arise in the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx. HNC is the sixth most common type of cancer, representing ~6% of all cancer cases and accounting for an estimated 650,000 new cases and 350,000 cancer deaths worldwide each year. 1 Tobacco smoking and alcohol intake are considered the major risk factors for HNC; 2 however, only a small proportion of smokers and alcohol users develop HNC in their lifetime, suggesting that individual susceptibility might also be a significant factor in disease etiology. The Cancer Genome Atlas profiled 279 head and neck squamous cell carcinomas and provides a comprehensive landscape of the somatic genomic aberrations associated with HNC. 3 The gene encoding cytochrome P450 1A1 (CYP1A1) maps to chromosome 15 and encodes an aryl hydrocarbon hydrolase that plays a role in the metabolism of the carcinogenic polycyclic aromatic hydrocarbons that are present in tobacco smoke. Previous studies have demonstrated that an amino acid substitution from isoleucine to valine in codon 462 (rs1048943, A4889G) in exon 7 of CYP1A1 enhances the 
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Wang et al catalytic activity of the cytochrome P450 1A1 protein 4, 5 and influences the risk of several cancers. [6] [7] [8] [9] [10] To date, a number of epidemiological studies that have explored the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC have been reported. However, the results of these studies have been conflicting rather than conclusive. Thus, we conducted a cumulative meta-analysis of eligible published studies to further evaluate the association between the Ile462Val polymorphism and HNC risk.
Materials and methods literature source and analytical methods
We searched the Medline/PubMed, EMBASE, and Web of Science databases for articles published until December 31, 2015, using various combinations of the following keywords in the search parameters: HNC, oral cancer, oral cavity cancer, pharyngeal cancer, laryngeal cancer, CYP1A1, cytochrome P450 1A1, rs1048943, polymorphism, and variant. In addition, we manually searched the reference list of relevant publications to identify additional studies.
The selection criteria of the eligible publications included the following: 1) the study that evaluated the CYP1A1 Ile462Val polymorphism and the risk of HNC; 2) the publication that reported a case-control study or cohort study; 3) the publication that reported all data regarding the genotype of the CYP1A1 Ile462Val polymorphism that was required to calculate the odds ratio (OR) with a 95% confidence interval (CI); and 4) the study that used controls verified to have no clinical evidence of a malignancy. Accordingly, reviews and publications of overlapping studies were excluded. In the context of publications with overlapping data, those that included more data were preferentially used in the study. In total, 45 published studies evaluating the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC were identified. We reviewed all the articles in accordance with the criteria defined earlier and excluded nine reviews and two publications with overlapping data. Ultimately, 34 studies were deemed to be eligible for the present study. One additional article 45 was included in the oral cancer subgroup analysis only.
Data extraction
Data were extracted, analyzed by two investigators, and entered into an electronic database. The following information was collected from each study: author, year of publication, country, ethnicity, the source of control (hospital-based controls, which mean controls from hospital, and populationbased controls, which mean controls from randomly selected healthy individuals), study population size, genotype frequency, and tumor type. The key characteristics of the eligible studies are summarized in Table 1 .
Quantitative data synthesis
A cumulative meta-analysis was performed to assess the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC. 46 The Cochrane Q statistics test was used to examine heterogeneity. 47 The data were combined using either a fixed-effects model or a random-effects model depending on the results of the heterogeneity test. The fixed-effects model was applied if no heterogeneity was detected. In all other cases, the random-effects model was applied. 47 A funnel plot was created to assess publication bias. Begg's test (a linear regression approach used to measure funnel plot asymmetry on the natural logarithm scale of the OR) 48 was used to evaluate the symmetry of the funnel plot. A sensitivity analysis was conducted in which we sequentially removed each eligible study from the pooled data. 46 The pooled OR of all the studies evaluated in this metaanalysis was calculated to evaluate the significance of the Ile/ Val+Val/Val vs the Ile/Ile genotype in HNC.
All the statistical analyses were conducted using the STATA 10.0 software package (StataCorp LP, College Station, TX, USA). All the tests were two-sided, and a P-value of #0.05 was considered to be statistically significant. Table 1 lists some general information associated with the eligible studies, including the first author, year of publication, country, ethnicity of the patients, source of controls, tumor subtype, and study population size. We identified a total of 34 studies that included 6,367 cases and 6,395 controls that evaluated the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC.
Results

Meta-analysis databases
Test of heterogeneity
No heterogeneity was observed for the CYP1A1 Ile/Val+Val/ Val genotype vs the Ile/Ile genotype in the subgroup analyses of patients with pharyngeal cancer and Caucasian patients. Therefore, we calculated the pooled ORs for these two groups using the fixed-effects model. The random-effects model was used to calculate the pooled OR for the remaining subgroup analyses. Table 2) . No significant association between the CYP1A1 Ile462Val polymorphism and the risk of oral cancer was observed. The pooled OR associated with the risk of oral cancer was 1.181 (95% CI: 0.930-1.500; Table 2 ).
Quantitative data synthesis
In the subgroup analyses of patients stratified by ethnicity, we observed an increased risk of HNC in Asians with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype, with a pooled OR of 1.371 (95% CI: 1.111-1.693; Table 2 ). No significant association between the CYP1A1 Ile462Val polymorphism and the risk of HNC in Caucasians was observed. The pooled OR in this subgroup was 1.138 (95% CI: 0.941-1.376; Table 2 ).
In the subgroup analysis in which the data were stratified according to the source of controls used in the study, we observed an increased risk of HNC associated with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype in patients from studies that used hospitalbased controls (OR =1.329, 95% CI: 1.138-1.551), but no significant association was observed in patients from studies that used population-based controls (OR =1.013, 95% CI: 0.606-1.694; Table 2 ).
Bias diagnosis
The publication bias was evaluated using a funnel plot analysis. The shape of the funnel plot appeared roughly symmetrical (Figure 2) , and the results of Begg's test suggested that publication bias would not significantly affect the summary estimates.
sensitivity analysis
To determine the impact of the individual data sets on the pooled OR, we conducted a sensitivity analysis in which each eligible study was consecutively omitted from the pooled data. The pooled OR was not significantly affected by the sequential deletion of individual studies, indicating that the results of this study are reliable and robust (Figure 3 ). 
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Discussion
Although two previously published meta-analyses evaluated the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC, 49, 50 careful examination of these data reveals several key issues worth noting. First, Qin et al mistakenly included a study published by Cascorbi et al 51 that evaluated the association between the −463G/A variant of the myeloperoxidase gene and the risk of cancer of the aerodigestive tract in their meta-analysis (supplemental Table 1 and supplemental references in the study of Qin et al 50 ) . Similarly, Qin et al also mistakenly included a study published by Bufalo et al 52 that evaluated the association between the CYP1A1 Ile462Val polymorphism and the susceptibility of thyroid cancer in their metaanalysis (supplemental Table 1 16 ). In addition, three eligible articles 12, 13, 27 were not included in the study by Liu et al. 49 Finally, although Sato et al reported that the CYP1A1 Ile462Val polymorphism was associated with an increased risk of oral cancer, 18 these data were not included in the oral cancer subgroup analysis in the Liu et al's study (Figure 2A in Liu et al 49 ). Together, these observations indicate that current data describing the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC are not entirely reliable. Three recent studies 41, 43, 44 on this topic have been subsequently published; however, further verification of the association between the CYP1A1 Ile462Val polymorphism and the risk of HNC is still required. The cumulative metaanalysis reported here was conducted to verify the association of the CYP1A1 Ile462Val polymorphism with the risk of HNC using data from a total of 34 studies that evaluated 6,367 cases and 6,395 controls. The goal of this study was to provide comprehensive and conclusive evidence regarding the association of the CYP1A1 Ile462Val polymorphism with the risk of HNC. Overall, we observed an increased risk of HNC in patients with the Ile/Val+Val/Val genotype compared to those with the Ile/Ile genotype. We also observed an increased risk of HNC in patients with the Ile/Val+Val/ Val genotype compared to those with the Ile/Ile genotype in various subgroups (laryngeal cancer, pharyngeal cancer, Asians, and patients in studies that used hospital-based controls).
The potential limitations of this meta-analysis should also be acknowledged. First, only published articles were selected in this study; therefore, publication bias might have influenced the results. To address this issue, we evaluated the eligible studies using Begg's test and determined that the likelihood of publication bias was negligible. Second, although some confounding variables were well balanced between studies, different studies might have used different inclusion criteria and different sources of controls. These factors should be taken into account when interpreting the pooled data. To address this issue, we conducted subgroup analyses of patients in studies that used hospital-based controls and those that used population-based controls. Third, this cumulative meta-analysis is based on an unadjusted estimate; therefore, a more precise analysis accounting for adjusted factors should be carried out in the future.
Conclusion
Our results suggest that the CYP1A1 Ile462Val polymorphism is associated with an increased risk of HNC, particularly in laryngeal cancer and pharyngeal cancer. The verification of our findings requires additional well-designed studies evaluating large sample sizes.
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